Pharma’s Search for Redox-Modulating Therapeutics
Dr. Duncan Emerton, Vice-President of Citeline, United Kingdom, will join Redox Medicine 2024 this June to discuss citeline's latest findings in his talk title: "Pharma’s Search for Redox-Modulating Therapeutics".
In his talk, Dr. Emerton will cover the following key points:
- Indications in which redox imbalance is linked to disease pathogenesis (e.g., long list)
- Key targets which modulate redox signalling in cellular homeostasis (e.g., NRF2/KEAP1, FOXO, NFkB, HIF, etc.)
- Pharma’s progress in developing medicines toward novel targets (i.e., stats from Citeline data sets by phase, company and indication)
- Outlook (i.e., how is redox medicine R&D likely to evolve?)
- Key Takeaways
About Citeline
Citeline is supporting Redox Medicine 2024. Citeline (a Norstella Company) powers a full suite of complementary business intelligence offerings to meet the evolving needs of health science professionals to accelerate the connection of treatments to patients and patients to treatments. Learn more.
Redox Medicine 2024 Speaker Line-up.
Redox Medicine Society
Redox Medicine 2024 Conference
June 27-28 - Paris, France
Press Releases | Newsletters Archive | LinkedIn
